{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T03:00:56Z","timestamp":1777777256742,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Clinical Research Bursary from Cancer Research-UK","award":["C54914\/A20558"],"award-info":[{"award-number":["C54914\/A20558"]}]},{"name":"a joint scholarship from Queen's University of Belfast and the Chinese Scholarship Council","award":["CSC201708060458"],"award-info":[{"award-number":["CSC201708060458"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pre-clinical studies have shown that furosemide slows cancer cell growth by acting on the Na-K-2Cl transporter, particularly for gastric cancer cells. However, epidemiological studies have not investigated furosemide use and mortality in gastroesophageal cancer patients. Consequently, we conducted a population-based study to investigate whether furosemide use is associated with reduced cancer-specific mortality in esophageal\/gastric cancer patients.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cohort of patients newly diagnosed with esophageal or gastric cancer between 1998 and 2013 were identified from English cancer registries and linked to the Clinical Practice Research Datalink to provide prescription records and the Office of National Statistics to provide death data up to September 2015. Time-dependant Cox-regression models were used to calculate hazard ratios (HRs) comparing cancer-specific mortality in furosemide users with non-users. Analyses were repeated restricting to patients with common furosemide indications (heart failure, myocardial infarction, edema or hypertension) to reduce potential confounding.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The cohort contained 2708 esophageal cancer patients and 2377 gastric cancer patients, amongst whom 1844 and 1467 cancer-specific deaths occurred, respectively. Furosemide use was not associated with reduced cancer-specific mortality overall (adjusted HR in esophageal cancer\u2009=\u20091.28, 95% CI 1.10, 1.50 and in gastric cancer\u2009=\u20091.27, 95% CI 1.08, 1.50) or when restricted to patients with furosemide indications before cancer diagnosis (adjusted HR in esophageal cancer\u2009=\u20091.07, 95% CI 0.88, 1.30 and in gastric cancer\u2009=\u20091.18, 95% CI 0.96, 1.46).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this large population-based cohort study, furosemide was not associated with reduced cancer-specific mortality in patients with esophageal or gastric cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-019-6242-8","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T20:44:43Z","timestamp":1572468283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Furosemide use and survival in patients with esophageal or gastric cancer: a population-based cohort study"],"prefix":"10.1186","volume":"19","author":[{"given":"Peipei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00dana C.","family":"McMenamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Spence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian T.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen G.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2689-4335","authenticated-orcid":false,"given":"Chris R.","family":"Cardwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"issue":"6","key":"6242_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"6242_CR2","volume-title":"Cancer Survival in England: Patients Diagnosed between 2011 and 2015 and Followed up to 2016","author":"Office for National Statistics","year":"2016","unstructured":"Office for National Statistics. Cancer Survival in England: Patients Diagnosed between 2011 and 2015 and Followed up to 2016. 2016. \n                    https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/cancersurvivalinengland\/adultstageatdiagnosisandchildhoodpatientsfollowedupto2016\n                    \n                  ."},{"issue":"9100","key":"6242_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0140-6736(97)08417-1","volume":"351","author":"G Cotter","year":"1998","unstructured":"Cotter G, Metzkor E, Kaluski E F, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351(9100):389\u201393.","journal-title":"Lancet"},{"key":"6242_CR4","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1111\/j.1751-7133.2010.00172.x","volume":"16","author":"FG Michael","year":"2010","unstructured":"Michael FG. Diuretic Management in Heart Failure. Congest Hear Fail. 2010;16:S68\u201372.","journal-title":"Congest Hear Fail"},{"issue":"1","key":"6242_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jch.12237","volume":"16","author":"MA Weber","year":"2014","unstructured":"Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the Management of Hypertension in the community. J Clin Hypertens. 2014;16(1):14\u201326.","journal-title":"J Clin Hypertens"},{"issue":"5","key":"6242_CR6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1345\/aph.1C320","volume":"37","author":"RJ Elwell","year":"2003","unstructured":"Elwell RJ, Spencer AP, Eisele G. Combined furosemide and human albumin treatment for diuretic-resistant edema. Ann Pharmacother. 2003;37(5):695\u2013700.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"6242_CR7","doi-asserted-by":"publisher","first-page":"F11","DOI":"10.1152\/ajprenal.00119.2002","volume":"284","author":"SS Shankar","year":"2003","unstructured":"Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Physiol. 2003;284(1):F11\u201321.","journal-title":"Am J Physiol Physiol"},{"issue":"19","key":"6242_CR8","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/BF01716719","volume":"60","author":"H Oberleithner","year":"1982","unstructured":"Oberleithner H, Giebisch G, Lang F, et al. Cellular mechanism of the furosemide sensitive transport system in the kidney. Klin Wochenschr. 1982;60(19):1173\u20139.","journal-title":"Klin Wochenschr"},{"issue":"2","key":"6242_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.gendis.2015.02.007","volume":"2","author":"SN Orlov","year":"2015","unstructured":"Orlov SN, Koltsova SV, Kapilevich LV, et al. NKCC1 and NKCC2: the pathogenetic role of cation-chloride cotransporters in hypertension. Genes Dis. 2015;2(2):186\u201396.","journal-title":"Genes Dis"},{"issue":"1","key":"6242_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/(SICI)1097-4652(200001)182:1<109::AID-JCP12>3.0.CO;2-A","volume":"182","author":"R Panet","year":"2000","unstructured":"Panet R, Marcus M, Atlan H. Overexpression of the Na+\/K+\/cl? Cotransporter gene induces cell proliferation and phenotypic transformation in mouse fibroblasts. J Cell Physiol. 2000;182(1):109\u201318.","journal-title":"J Cell Physiol"},{"issue":"3","key":"6242_CR11","doi-asserted-by":"publisher","first-page":"L510","DOI":"10.1152\/ajplung.00021.2004","volume":"287","author":"LM Iwamoto","year":"2004","unstructured":"Iwamoto LM, Fujiwara N, Nakamura KT, et al. Na-K-2Cl cotransporter inhibition impairs human lung cellular proliferation. Am J Physiol Cell Mol Physiol. 2004;287(3):L510\u20134.","journal-title":"Am J Physiol Cell Mol Physiol"},{"issue":"6","key":"6242_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2170\/physiolsci.RP010806","volume":"56","author":"A Shiozaki","year":"2006","unstructured":"Shiozaki A, Miyazaki H, Niisato N, et al. Furosemide, a blocker of Na+\/K+\/2Cl\u2212 Cotransporter, diminishes proliferation of poorly differentiated human gastric Cancer cells by affecting G0\/G1 state. J Physiol Sci. 2006;56(6):401\u20136.","journal-title":"J Physiol Sci"},{"issue":"22","key":"6242_CR13","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.3748\/wjg.v20.i22.6844","volume":"20","author":"A Shiozaki","year":"2014","unstructured":"Shiozaki A, Nako Y, Ichikawa D, et al. Role of the Na +\/K +\/2Cl\u2212 cotransporter NKCC1 in cell cycle progression in human esophageal squamous cell carcinoma. World J Gastroenterol. 2014;20(22):6844\u201359.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"6242_CR14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827\u201336.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"6242_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2296-11-1","volume":"11","author":"NF Khan","year":"2010","unstructured":"Khan NF, Perera R, Harper S, et al. Adaptation and validation of the Charlson index for read\/OXMIS coded databases. BMC Fam Pract. 2010;11(1):1.","journal-title":"BMC Fam Pract"},{"key":"6242_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-3-211-89836-9","volume-title":"Dictionary of Pharmaceutical Medicine","author":"G Nahler","year":"2009","unstructured":"Nahler G. Defined daily dose (DDD). In: Dictionary of Pharmaceutical Medicine. Vienna: Springer Vienna; 2009. p. 49."},{"key":"6242_CR17","volume-title":"The English Indices of Deprivation 2010 - Technical Report","author":"DCLG","year":"2010","unstructured":"DCLG. The English Indices of Deprivation 2010 - Technical Report.; 2010. \n                    www.communities.gov.ukcommunity\n                    \n                  , opportunity, prosperity. Accessed 15 Oct 2018."},{"key":"6242_CR18","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","volume":"391","author":"N Conrad","year":"2018","unstructured":"Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391:572\u201380.","journal-title":"Lancet"},{"issue":"669","key":"6242_CR19","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.3399\/bjgp18X695465","volume":"68","author":"A Cassell","year":"2018","unstructured":"Cassell A, Edwards D, Harshfield A, et al. The epidemiology of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract. 2018;68(669):e245\u201351.","journal-title":"Br J Gen Pract"},{"issue":"19","key":"6242_CR20","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","volume":"367","author":"SF Nielsen","year":"2012","unstructured":"Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced Cancer-related mortality. N Engl J Med. 2012;367(19):1792\u2013802.","journal-title":"N Engl J Med"},{"issue":"4","key":"6242_CR21","doi-asserted-by":"publisher","first-page":"e0152402","DOI":"10.1371\/journal.pone.0152402","volume":"11","author":"PC Elwood","year":"2016","unstructured":"Elwood PC, Morgan G, Pickering JE, et al. Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies. Ali R, ed. PLoS One. 2016;11(4):e0152402.","journal-title":"PLoS One"},{"issue":"4","key":"6242_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, St\u00fcrmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol reports. 2015;2(4):221\u20138.","journal-title":"Curr Epidemiol reports"},{"key":"6242_CR23","doi-asserted-by":"publisher","first-page":"b5087","DOI":"10.1136\/bmj.b5087","volume":"340","author":"LE L\u00e9vesque","year":"2010","unstructured":"L\u00e9vesque LE, Hanley JA, Kezouh A, et al. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.","journal-title":"BMJ"},{"issue":"19","key":"6242_CR24","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1093\/jnci\/djt211","volume":"105","author":"J Chubak","year":"2013","unstructured":"Chubak J, Boudreau DM, Wirtz HS, et al. Threats to validity of nonrandomized studies of Postdiagnosis exposures on Cancer recurrence and survival. JNCI J Natl Cancer Inst. 2013;105(19):1456\u201362.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"11","key":"6242_CR25","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/oxfordjournals.aje.a009758","volume":"149","author":"M Salas","year":"1999","unstructured":"Salas M, Hotman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol. 1999;149(11):981\u20133.","journal-title":"Am J Epidemiol"},{"issue":"11","key":"6242_CR26","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1158\/1055-9965.EPI-17-0346","volume":"26","author":"L Chen","year":"2017","unstructured":"Chen L, Chubak J, Boudreau DM, et al. Use of antihypertensive medications and risk of adverse breast Cancer outcomes in a SEER-Medicare population. Cancer Epidemiol Biomark Prev. 2017;26(11):1603\u201310.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"9","key":"6242_CR27","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/sj.bjc.6604686","volume":"99","author":"A\u00d8 Jensen","year":"2008","unstructured":"Jensen A\u00d8, Thomsen HF, Engebjerg MC, et al. Use of photosensitising diuretics and risk of skin cancer: a population-based case\u2013control study. Br J Cancer. 2008;99(9):1522.","journal-title":"Br J Cancer"},{"issue":"4","key":"6242_CR28","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/joim.12629","volume":"282","author":"A Potteg\u00e5rd","year":"2017","unstructured":"Potteg\u00e5rd A, Hallas J, Olesen M, et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med. 2017;282(4):322\u201331.","journal-title":"J Intern Med"},{"issue":"2","key":"6242_CR29","first-page":"114","volume":"6","author":"IW Mak","year":"2014","unstructured":"Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6(2):114\u20138.","journal-title":"Am J Transl Res"},{"issue":"5","key":"6242_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1046\/j.1365-2125.1998.00701.x","volume":"45","author":"LA Garc\u00eda Rodr\u00edguez","year":"2002","unstructured":"Garc\u00eda Rodr\u00edguez LA, P\u00e9rez GS. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol. 2002;45(5):419\u201325.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"6242_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00045391-200205000-00005","volume":"9","author":"LB Signorello","year":"2002","unstructured":"Signorello LB, McLaughlin JK, Lipworth L, et al. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther. 2002;9(3):199\u2013205.","journal-title":"Am J Ther"},{"issue":"2","key":"6242_CR32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0885-3924(98)00037-2","volume":"16","author":"CW Lee","year":"1998","unstructured":"Lee CW, Bociek G, Faught W. A survey of practice in management of malignant ascites. J Pain Symptom Manag. 1998;16(2):96\u2013101.","journal-title":"J Pain Symptom Manag"},{"issue":"5","key":"6242_CR33","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0016-5085(19)31869-4","volume":"73","author":"J Zink","year":"1977","unstructured":"Zink J, Greenway CV. Control of ascites absorption in anesthetized cats: effects of intraperitoneal pressure, protein, and furosemide diuresis. Gastroenterology. 1977;73(5):1119\u201324.","journal-title":"Gastroenterology"},{"issue":"6","key":"6242_CR34","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jamcollsurg.2004.01.035","volume":"198","author":"RA Adam","year":"2004","unstructured":"Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg. 2004;198(6):999\u20131011.","journal-title":"J Am Coll Surg"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6242-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:29:51Z","timestamp":1603844991000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6242-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6242"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6242-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,29]]},"assertion":[{"value":"27 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Independent Scientific Advisory Committee for Medicines and Healthcare products Regulatory Agency Database Research (protocol number: 15_096RMn3). This study is based in part on data from the CPRD obtained under licence from the UK Medicines and Healthcare Products Regulatory Agency. The CPRD collects de-identified data from a network of GP practices therefore no written informed consent was obtained. The interpretation and conclusions contained in this study are those of the authors alone.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1017"}}